Trials / Completed
CompletedNCT04058535
Clinical Study of ALT-L9 to Determine Safety, Efficacy and Pharmacokinetics in Neovascular AMD
A Phase I Clinical Study of ALT-L9 in Patients With Neovascular Age-related Macular Degeneration
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Alteogen, Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety, efficacy and pharmacokinetics of repeated intravitreal administration of ALT-L9 2 mg/50uL compared with Eylea in patients with neovascular Age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Eylea | Aflibercept |
| BIOLOGICAL | ALT-L9 | Aflibercept biosimilar |
Timeline
- Start date
- 2020-02-05
- Primary completion
- 2020-12-22
- Completion
- 2020-12-22
- First posted
- 2019-08-15
- Last updated
- 2022-01-20
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04058535. Inclusion in this directory is not an endorsement.